Rationale, background, and design of the randomized angiotensin receptor antagonist-angiotensin-converting enzyme inhibitor study (RAAS)

American Journal of Cardiology

Volumn 78, Issue 10, 1996, Pages 1129-1131

  Pitt, Bertram ^a   Chang, Paul ^b   Grossman, William ^b   Dunlay, Mary ^b   Timmermans, Pieter B M W W M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; BIPHENYL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMIDAZOLE DERIVATIVE; LOSARTAN; TETRAZOLE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG COMBINATION; HEART LEFT VENTRICLE FUNCTION; HUMAN; METHODOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TITRIMETRY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIPHENYL COMPOUNDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENALAPRIL; HEART FAILURE, CONGESTIVE; HUMANS; IMIDAZOLES; LOSARTAN; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RESEARCH DESIGN; TETRAZOLES; TITRIMETRY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0030588455     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)90065-X     Document Type: Article

References (20)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
2. Timmermans P BMWM, Smight RD. A new class of therapeutic agents: the angiotensin II receptor antagonists. Cardiologia 1994;39:397-400.
3. Guyatt OH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6 minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923.
4. Rector TS, Cohn JN, with the Pimobendan Multicenter Research Group. Assessment of patient outcome with the Minnesota living and heart failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017-1025.
5. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG, for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-155.
6. Nakashima M, Mombouli J-V, Taylor AA, Vanhoutte PM. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 1993;92:2867-2871.
7. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, Zelir R. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69:1596-1601.
8. Rafflenbuhl W, Bassenge E, Lichtlen P. Konkurrenz zwischen endothelabhangiger und nitroglycerin-induzierter koronarer vasodilatation. Z Kardiol 1989;78(suppl 2):45-47.
9. Kuga T, Egashire K, Mohri M, Tsutsui H, Harasawa Y, Urabe Y, Ando S, Shimokawa H, Takeshita A. Bradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivo. Circulation 1995;92:183-189.
10. Aldigier JC, Huang H, Dalmay F, Lartigue M, Baussant T, Chassain AP, Leroux-Robert, Galen FX. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993;21:289-295.
11. Gavras H, Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens 1991;9:385-392.
12. Urata H, Healy B, Bernadine H, Stewart RW, Bumpus FM, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res 1990;66:883-890.
13. Tanaka M, Ohnishi J, Ozawa Y, Sugimoto M, Usuki S, Naruse M, Murakami K, Miyazaki H. Characterization of angiotensin II receptor type 2 during differentiation and apoptosis of rat ovarian cultured granulosa cells. Biochem Biophys Res Commun 1995;207:593-598.
14. Chiu AT, McCall DE, Price WA Jr, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PBMWM. In vitro pharmacology of DuP753. Am J Hypertens 1991;4:282S-287S.
15. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-1350.
16. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-445.
17. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-1609.
18. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-1973.
19. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
20. Pitt B, Chang P, Timmermans P. Angiotensin II receptor antagonists in heart failure: rationale and design of the Evaluation of Losartan in the Elderly (ELITE) trial. Cardiovasc Drugs Ther 1995;9:693-700.